Stony Brook-developed cancer drug advances to human clinical trials
A promising new cancer chemotherapeutic agent from a taxane class of natural compounds – anti-cancer agents designed to block cell division and trigger the programmed cell death to treat sold tumors – originally developed by researchers at Stony Brook University has entered human clinical trials.
Read original article on The Medical News →Related news
-
Single iron infusion improved exercise capacity in people with the most common form of heart failure
United Kingdom
-
Lucky Bird Found in Storm Drain a Mile From Home After Passing Driver Happens to Spot it Hopping in
United Kingdom
-
A 24-hour fast triggers a surprising repair response in the gut
United States
-
MIT scientists turn immune cells into cancer killers inside the body
United States
-
Climate change and funding cuts threaten malaria targets: what SADC countries can do
Australia
-
Good News in History, November 8
United Kingdom
-
Stronger flu shot linked to nearly 55% lower Alzheimer's risk
United States
-
Financial incentives nearly double quit rates among underserved people who smoke in national study
United Kingdom